miR-217 regulates tumor growth and apoptosis by targeting the MAPK signaling pathway in colorectal cancer

Zhang,Nan; Lu,Canrong; Chen,Lin

doi:10.3892/ol.2016.5249

miR-217 regulates tumor growth and apoptosis by targeting the MAPK signaling pathway in colorectal cancer

Authors:
- Nan Zhang
- Canrong Lu
- Lin Chen
View Affiliations

Affiliations: General Surgery Center Department of Chinese PLA General Hospital, Beijing 100853, P.R. China
Published online on: October 13, 2016 https://doi.org/10.3892/ol.2016.5249
Pages: 4589-4597
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miR)-217 has been reported to participate in carcinogenesis and tumor progression in several cancers; however, its expression and biological functions in colorectal cancer (CRC) are still unclear. The present study demonstrated that miR-217 expression was significantly higher in matched adjacent noncancerous tissues than in CRC tissues (P<0.001). In addition, it was observed that low‑grade CRC exhibited greater expression of miR‑217 compared with high‑grade CRC (P<0.05). Kaplan‑Meier survival and Cox regression analyses revealed that overall survival rates were significantly poorer in the low‑expression group relative to the high‑expression group (P<0.005). Next, a potential miR‑217 target, mitogen‑activated protein kinase (MAPK) 1, was identified. Upregulation of miR‑217 could significantly downregulate MAPK1 expression. CRC cells overexpressing miR‑217 exhibited cell growth inhibition by significant enhancement of apoptosis in vitro. The present study further investigated the MAPK signaling pathway to verify the mechanisms, and revealed that KRAS and Raf‑1 expression was downregulated in miR‑217‑overexpressing RKO cells. Taken together, our results revealed that miR‑217 inhibits tumor growth and enhances apoptosis in CRC, and that this is associated with the downregulation of MAPK signaling. These results indicate that miR‑217 is a promising therapeutic target for the treatment of CRC.

View Figures

View References

1	Debarros M and Steele SR: Colorectal cancer screening in an equal access healthcare system. J Cancer. 4:270–280. 2013. View Article : Google Scholar : PubMed/NCBI
2	Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet. 375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
3	Qaseem A, Denberg TD, Hopkins RH Jr, Humphrey LL, Levine J, Sweet DE and Shekelle P: Clinical Guidelines Committee of the American College of Physicians: Screening for colorectal cancer: A guidance statement from the American College of Physicians. Ann Intern Med. 156:378–386. 2012. View Article : Google Scholar : PubMed/NCBI
4	Ragnhammar P, Hafström L, Nygren P and Glimelius B: SBU-group. Swedish Council of Technology Assessment in Health Care: A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol. 40:282–308. 2001. View Article : Google Scholar : PubMed/NCBI
5	Bergsland EK: Is more not better? Combination therapies in colorectal cancer treatment. Hematol Oncol Clin North Am. 29:85–116. 2015. View Article : Google Scholar : PubMed/NCBI
6	Saltz LB and Minsky B: Adjuvant therapy of cancers of the colon and rectum. Surg Clin North Am. 82:1035–1058. 2002. View Article : Google Scholar : PubMed/NCBI
7	Bauer TW and Spitz FR: Adjuvant and neoadjuvant chemoradiation therapy for primary colorectal cancer. Surg Oncol. 7:175–181. 1998. View Article : Google Scholar : PubMed/NCBI
8	Moss JA: Gene therapy review. Radiol Technol. 86:155–184. 2014.PubMed/NCBI
9	Roth JA and Cristiano RJ: Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst. 89:21–39. 1997. View Article : Google Scholar : PubMed/NCBI
10	Kalla R, Ventham NT, Kennedy NA, Quintana JF, Nimmo ER, Buck AH and Satsangi J: MicroRNAs: New players in IBD. Gut. 64:504–517. 2015. View Article : Google Scholar : PubMed/NCBI
11	Xue J, Niu J, Wu J and Wu ZH: MicroRNAs in cancer therapeutic response: Friend and foe. World J Clin Oncol. 5:730–743. 2014. View Article : Google Scholar : PubMed/NCBI
12	Kong YW, Ferland-McCollough D, Jackson TJ and Bushell M: MicroRNAs in cancer management. Lancet Oncol. 13:e249–e258. 2012. View Article : Google Scholar : PubMed/NCBI
13	Menghini R, Casagrande V, Cardellini M, Martelli E, Terrinoni A, Amati F, Vasa-Nicotera M, Ippoliti A, Novelli G, Melino G, et al: MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation. 120:1524–1532. 2009. View Article : Google Scholar : PubMed/NCBI
14	Xia H, Ooi LL and Hui KM: MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology. 58:629–641. 2013. View Article : Google Scholar : PubMed/NCBI
15	Zhao WG, Yu SN, Lu ZH, Ma YH, Gu YM and Chen J: The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis. 31:1726–1733. 2010. View Article : Google Scholar : PubMed/NCBI
16	Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I, Gunn A, Nakagawa Y, Shimano H, Todorov I, et al: TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol. 11:881–889. 2009. View Article : Google Scholar : PubMed/NCBI
17	Voong LN, Slater AR, Kratovac S and Cressman DE: Mitogen-activated protein kinase ERK1/2 regulates the class II transactivator. J Biol Chem. 283:9031–9039. 2008. View Article : Google Scholar : PubMed/NCBI
18	Giehl K, Skripczynski B, Mansard A, Menke A and Gierschik P: Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: Implications for cell proliferation and cell migration. Oncogene. 19:2930–2942. 2000. View Article : Google Scholar : PubMed/NCBI
19	Lu Y, Xiao T, Zhang F, Chen Y, Liu Y, Li Y, Chen YD, Li Z and Guan M: Effect of mitochondrial tRNA(Lys) mutation on the clinical and biochemical characteristics of Chinese essential hypertensive subjects. Biochem Biophys Res Commun. 454:500–504. 2014. View Article : Google Scholar : PubMed/NCBI
20	Wang Q, Qian J, Wang J, Luo C, Chen J, Hu G and Lu Y: Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells. J Neurooncol. 112:73–82. 2013. View Article : Google Scholar : PubMed/NCBI
21	Hui AB, Shi W, Boutros PC, Miller N, Pintilie M, Fyles T, McCready D, Wong D, Gerster K, Waldron L, Jurisica I, et al: Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest. 89:597–606. 2009. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Wang Q, Wang JY, Zhang XP, Lv ZW, Fu D, Lu YC, Hu GH, Luo C and Chen JX: RLIP76 is overexpressed in human glioblastomas and is required for proliferation, tumorigenesis and suppression of apoptosis. Carcinogenesis. 34:916–926. 2013. View Article : Google Scholar : PubMed/NCBI
24	Subramanian M and Shaha C: Upregulation of Bcl-2 through ERK phosphorylation is associated with human macrophage survival in an estrogen microenvironment. J Immunol. 179:2330–2338. 2007. View Article : Google Scholar : PubMed/NCBI
25	Vitagliano O, Addeo R, D'Angelo V, Indolfi C, Indolfi P and Casale F: The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: Implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches. Expert Rev Hematol. 6:587–597. 2013. View Article : Google Scholar : PubMed/NCBI
26	Lemieux E, Cagnol S, Beaudry K, Carrier J and Rivard N: Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer. Oncogene. 34:4914–4927. 2015. View Article : Google Scholar : PubMed/NCBI
27	Guo J, Feng Z, Huang Z, Wang H and Lu W: MicroRNA-217 functions as a tumor suppressor gene and correlates with cell resistance to cisplatin in lung cancer. Mol Cells. 37:664–671. 2014. View Article : Google Scholar : PubMed/NCBI
28	de Yébenes VG, Bartolomé-Izquierdo N, Nogales-Cadenas R, Pérez-Durán P, Mur SM, Martínez N, Di Lisio L, Robbiani DF, Pascual-Montano A, Cañamero M, et al: MiR-217 is an oncogene that enhances the germinal center reaction. Blood. 124:229–239. 2014. View Article : Google Scholar : PubMed/NCBI
29	Joshi S and Platanias LC: Mnk kinase pathway: Cellular functions and biological outcomes. World J Biol Chem. 5:321–333. 2014. View Article : Google Scholar : PubMed/NCBI
30	Bates DJ and Lewis LD: Manipulating the apoptotic pathway: Potential therapeutics for cancer patients. Br J Clin Pharmacol. 76:381–395. 2013. View Article : Google Scholar : PubMed/NCBI
31	Zhang T and Saghatelian A: Emerging roles of lipids in BCL-2 family-regulated apoptosis. Biochim Biophys Acta. 1831:1542–1554. 2013. View Article : Google Scholar : PubMed/NCBI
32	Ye L, Yuan G, Xu F, Sun Y, Chen Z, Chen M, Li T, Sun P, Li S and Sun J: The small-molecule compound BM-1197 inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers apoptotic cell death in human colorectal cancer cells. Tumour Biol. 36:3447–3455. 2015. View Article : Google Scholar : PubMed/NCBI
33	Zhao SL, Hong J, Xie ZQ, Tang JT, Su WY, Du W, Chen YX, Lu R, Sun DF and Fang JY: TRAPPC4-ERK2 interaction activates ERK1/2, modulates its nuclear localization and regulates proliferation and apoptosis of colorectal cancer cells. PLoS One. 6:e232622011. View Article : Google Scholar : PubMed/NCBI
34	Abdel-Magid AF: ERK2 inhibitors may provide treatment for cancer. ACS Med Chem Lett. 4:576–577. 2013. View Article : Google Scholar : PubMed/NCBI
35	Adams JM and Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science. 281:1322–1326. 1998. View Article : Google Scholar : PubMed/NCBI
36	Wang D, Weng Q, Zhang L, He Q and Yang B: VEGF and Bcl-2 interact via MAPKs signaling pathway in the response to hypoxia in neuroblastoma. Cell Mol Neurobiol. 29:391–401. 2009. View Article : Google Scholar : PubMed/NCBI
37	Scheid MP, Schubert KM and Duronio V: Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase. J Biol Chem. 274:31108–31113. 1999. View Article : Google Scholar : PubMed/NCBI
38	Orton RJ, Sturm OE, Vyshemirsky V, Calder M, Gilbert DR and Kolch W: Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway. Biochem J. 392:249–261. 2005. View Article : Google Scholar : PubMed/NCBI
39	Cheng Y, Zhang G and Li G: Targeting MAPK pathway in melanoma therapy. Cancer Metastasis Rev. 32:567–584. 2013. View Article : Google Scholar : PubMed/NCBI
40	Furukawa K and Hohmann S: Synthetic biology: Lessons from engineering yeast MAPK signalling pathways. Mol Microbiol. 88:5–19. 2013. View Article : Google Scholar : PubMed/NCBI
41	Pritchard AL and Hayward NK: Molecular pathways: Mitogen-activated protein kinase pathway mutations and drug resistance. Clin Cancer Res. 19:2301–2309. 2013. View Article : Google Scholar : PubMed/NCBI
42	Zassadowski F, Rochette-Egly C, Chomienne C and Cassinat B: Regulation of the transcriptional activity of nuclear receptors by the MEK/ERK1/2 pathway. Cell Signal. 24:2369–2377. 2012. View Article : Google Scholar : PubMed/NCBI
43	Collins MA and di Magliano M Pasca: Kras as a key oncogene and therapeutic target in pancreatic cancer. Front Physiol. 4:4072013.PubMed/NCBI
44	Sundaram MV: RTK/Ras/MAPK signaling. WormBook. 1–19. 2006.PubMed/NCBI